RxDoctor Payments Data

Hashim Gazi, MD

Interventional Cardiology · Tarzana, CANPI 1417373010

Payments from drug & device makers

$48,087in general payments, 2019–2025

Across 208 payments — averaging $231.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$28K
  • Boston Scientific$16K
  • Edwards Lifesciences$2K
  • Abiomed$740
  • Inari Medical, Inc.$196
  • Teleflex LLC$142
  • plus $922 from 14 others

What the payments were for

  • Grants$33,00069%
  • Travel & lodging$7,58016%
  • Food & beverage$7,47516%
  • Education$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,087 in reported general payments places this provider in the 75th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$410,224
Medicare patients
705
Services billed
3,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$73,018
EntrestoSacubitril/Valsartan22$20,112
BrilintaTicagrelor30$14,139
XareltoRivaroxaban15$12,771
Metoprolol Succinate123$1,294
ClopidogrelClopidogrel Bisulfate98$1,164
Ranolazine ErRanolazine15$964
Rosuvastatin Calcium50$856
Carvedilol103$765
Ezetimibe41$692
Atorvastatin Calcium82$635
Amlodipine Besylate103$445
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$416
Metoprolol Tartrate27$287
Lisinopril53$239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$119$73,01877 claims
NovartisEntresto$77$20,11222 claims
AstraZenecaBrilinta$57$14,13930 claims
Johnson & JohnsonXarelto$96$12,77115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →